🔗 Permalink

Inventor profile of:

Jürgen FREVERT

City:

Berlin

Country:

Germany

Published Applications:

Last publication date:

2022-01-13

Top Assignees for applications by Jürgen FREVERT

The entities that hold a legal rights for patent applications filed by inventor FREVERT Jürgen:

MERZ PHARMA GmbH &CO. KGaA 20 FRANKFURT am MAIN, Germany
MERZ PHARMA GMBH & CO. KGAA 1 Frankfurt an Main, Germany
MERZ PHARMA GmbH & CO. KGaA 1 FRAKFURT am MAIN, Germany
Merz Pharma GmbH & Co. KGaA 1 Frankfurt Au Main, Germany

Recent patent applications by FREVERT Jürgen

Jürgen FREVERT from Berlin, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2022-01-13

US20220010294A1

Chemistry; metallurgy

NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH INCREASED DURATION OF EFFECT

#2 | 2021-01-14

US20210008156A1

Human necessities

NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH INCREASED DURATION OF EFFECT

#3 | 2020-11-12

US20200354706A1

Chemistry; metallurgy

NOVEL RECOMBINANT BOTULINUM TOXIN WITH INCREASED DURATION OF EFFECT

#4 | 2020-04-30

US20200131494A1

Chemistry; metallurgy

Recombinant botulinum neurotoxins with increased duration of effect

#5 | 2020-02-13

US20200048624A1

Chemistry; metallurgy

Recombinant botulinum toxin with increased duration of effect

#6 | 2018-11-15

US20180327730A1

Chemistry; metallurgy

Recombinant clostridial neurotoxins with increased duration of effect

#7 | 2018-06-21

US20180169182A1

Human necessities

Recombinant clostridial neurotoxins with increased duration of effect

#8 | 2017-03-16

US20170072030A1

Human necessities

Neurotoxins exhibiting shortened biological activity

#9 | 2017-03-02

US20170058006A1

Chemistry; metallurgy

Recombinant clostridial neurotoxins with increased duration of effect

#10 | 2016-02-04

US20160030511A1

Human necessities

Neurotoxins exhibiting shortened biological activity

#11 | 2015-11-12

US20150322118A1

Chemistry; metallurgy

RECOMBINANT CLOSTRIDIAL NEUROTOXINS WITH ENHANCED MEMBRANE LOCALIZATION

#12 | 2015-08-20

US20150232828A1

Chemistry; metallurgy

METHOD FOR THE MANUFACTURING OF RECOMBINANT PROTEINS HARBOURING AN N-TERMINAL LYSINE

#13 | 2015-06-18

US20150166977A1

Chemistry; metallurgy

PEGylated mutated toxin

#14 | 2014-10-16

US20140308267A1

Chemistry; metallurgy

Neurotoxins exhibiting shortened biological activity

#15 | 2014-07-03

US20140187755A1

Chemistry; metallurgy

Clostridial neurotoxins with altered persistency

#16 | 2014-06-19

US20140170133A1

Human necessities

ALTERATION OF PROTEOLYTIC CLEAVAGE OF BOTULINUM NEUROTOXINS

#17 | 2014-02-13

US20140045760A1

Chemistry; metallurgy

Neurotoxins exhibiting shortened biological activity

#18 | 2013-06-20

US20130156747A1

Chemistry; metallurgy

PEGylated mutated clostridium botulinum toxin

#19 | 2012-05-03

US20120107362A1

Human necessities

Neurotoxins exhibiting shortened biological activity

#20 | 2011-12-01

US20110294747A1

Human necessities

PEGylated mutated toxin

#21 | 2011-09-08

US20110217287A1

Chemistry; metallurgy

Therapeutic composition comprising a botulinum neurotoxin

#22 | 2011-08-04

US20110189158A1

Chemistry; metallurgy

Clostridial neurotoxins with altered persistency

#23 | 2009-05-07

US20090118193A1

Human necessities

Pegylated mutated clostridium botulinum toxin

#24 | 2007-06-14

US20070134199A1

Human necessities

Formulation for a protein pharmaceutical without added human serum albumin (HSA)

InventorID:

298619 ⎘